Abetimus Sodium

Summary

Abetimus Sodium (CHEMBL2108835) is a phase-3 clinical-stage unknown; indicated across 2 conditions including lupus nephritis and systemic lupus erythematosus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108835
Name	Abetimus Sodium
Type	Unknown
Max phase	3

Also known as: Abetimus sodium, LJP 394, LJP-394, ABETIMUS SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lupus nephritis	3	MONDO:0005556	EFO:0005761
systemic lupus erythematosus	3	MONDO:0007915	MONDO:0007915

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).